JP2022519623A5 - - Google Patents
Info
- Publication number
- JP2022519623A5 JP2022519623A5 JP2021545659A JP2021545659A JP2022519623A5 JP 2022519623 A5 JP2022519623 A5 JP 2022519623A5 JP 2021545659 A JP2021545659 A JP 2021545659A JP 2021545659 A JP2021545659 A JP 2021545659A JP 2022519623 A5 JP2022519623 A5 JP 2022519623A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide sequence
- vector
- enhancer
- seq
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076698A JP2025118768A (ja) | 2019-02-05 | 2025-05-02 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801483P | 2019-02-05 | 2019-02-05 | |
| US62/801,483 | 2019-02-05 | ||
| US201962823281P | 2019-03-25 | 2019-03-25 | |
| US62/823,281 | 2019-03-25 | ||
| US201962916477P | 2019-10-17 | 2019-10-17 | |
| US62/916,477 | 2019-10-17 | ||
| PCT/US2020/015183 WO2020163102A1 (en) | 2019-02-05 | 2020-01-27 | Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076698A Division JP2025118768A (ja) | 2019-02-05 | 2025-05-02 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519623A JP2022519623A (ja) | 2022-03-24 |
| JP2022519623A5 true JP2022519623A5 (https=) | 2023-02-03 |
| JP7724157B2 JP7724157B2 (ja) | 2025-08-15 |
Family
ID=71947919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545659A Active JP7724157B2 (ja) | 2019-02-05 | 2020-01-27 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
| JP2025076698A Pending JP2025118768A (ja) | 2019-02-05 | 2025-05-02 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076698A Pending JP2025118768A (ja) | 2019-02-05 | 2025-05-02 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220195457A1 (https=) |
| EP (1) | EP3921326A4 (https=) |
| JP (2) | JP7724157B2 (https=) |
| KR (1) | KR20210133227A (https=) |
| CN (1) | CN113966400A (https=) |
| CA (1) | CA3128525A1 (https=) |
| IL (1) | IL284909A (https=) |
| SG (1) | SG11202107813RA (https=) |
| WO (1) | WO2020163102A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115707773A (zh) * | 2021-08-20 | 2023-02-21 | 中国科学院深圳先进技术研究院 | 一种利用交感神经控制血管内皮细胞异质性的方法 |
| US12054486B2 (en) | 2021-09-24 | 2024-08-06 | Xenon Pharmaceuticals Inc. | Pyridine derivatives and their use as sodium channel activators |
| WO2023108401A1 (zh) * | 2021-12-14 | 2023-06-22 | 深圳先进技术研究院 | 重组载体及其构建方法和应用 |
| JP2024545923A (ja) | 2021-12-30 | 2024-12-13 | リーゲル セラピューティクス，インコーポレイティッド | ナトリウム電位依存性チャネルアルファサブユニット１の発現を調節するための組成物、及びその使用 |
| GB2621102A (en) * | 2022-04-11 | 2024-02-07 | Univ Ramot | Treatment and Reversion of Dravet syndrome by CAV-2-Mediated Delivery of an SCN1A Expression Cassette |
| WO2023200700A2 (en) * | 2022-04-11 | 2023-10-19 | The Broad Institute, Inc. | Enhancers for directed expression of genes in neuronal cell populations, compositions and methods thereof |
| CN116024222B (zh) * | 2022-11-30 | 2023-12-22 | 湖南家辉生物技术有限公司 | 一种导致婴儿严重肌阵挛性癫痫的nac1基因突变体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101255424B (zh) * | 2007-11-26 | 2013-02-27 | 广州医学院第二附属医院 | 与癫痫相关scn1a基因的启动子及其构建方法和临床应用 |
| EP2635111B1 (en) * | 2010-11-05 | 2018-05-23 | The Board of Trustees of the Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
| US10682424B2 (en) * | 2015-03-31 | 2020-06-16 | New York University | Compositions and method for reducing seizures |
| MX2019011772A (es) * | 2017-04-03 | 2020-01-09 | Encoded Therapeutics Inc | Expresion transgenica selectiva de tejidos. |
-
2020
- 2020-01-27 KR KR1020217028274A patent/KR20210133227A/ko active Pending
- 2020-01-27 SG SG11202107813RA patent/SG11202107813RA/en unknown
- 2020-01-27 JP JP2021545659A patent/JP7724157B2/ja active Active
- 2020-01-27 US US17/428,538 patent/US20220195457A1/en active Pending
- 2020-01-27 WO PCT/US2020/015183 patent/WO2020163102A1/en not_active Ceased
- 2020-01-27 CN CN202080027324.8A patent/CN113966400A/zh active Pending
- 2020-01-27 EP EP20752944.7A patent/EP3921326A4/en active Pending
- 2020-01-27 CA CA3128525A patent/CA3128525A1/en active Pending
-
2021
- 2021-07-18 IL IL284909A patent/IL284909A/en unknown
-
2025
- 2025-05-02 JP JP2025076698A patent/JP2025118768A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022519623A5 (https=) | ||
| JP2024045199A5 (https=) | ||
| JP2020518259A5 (https=) | ||
| Federici et al. | Gene‐based treatment of motor neuron diseases | |
| JP2021522842A5 (https=) | ||
| JP2025118768A5 (https=) | ||
| JP2021534154A5 (https=) | ||
| JP6889154B2 (ja) | グルカゴン類似ペプチド−１受容体亢進剤を含む筋減少症治療用薬学組成物 | |
| JP2024517710A5 (https=) | ||
| JP2023545229A5 (https=) | ||
| WO2019183246A1 (en) | Compositions and methods of fas inhibition | |
| JP2024540537A5 (https=) | ||
| JP2020527167A5 (https=) | ||
| AU2021225696B2 (en) | Trans-splicing ribozyme specific to APOE4 RNA and use thereof | |
| JP2024133479A5 (https=) | ||
| EP4509606A1 (en) | Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof | |
| JP2023522883A5 (https=) | ||
| JP2023530379A5 (https=) | ||
| CN119365598A (zh) | 用于治疗单基因神经发育障碍的组合物和方法 | |
| CN118043461A (zh) | 方法 | |
| US20160108431A1 (en) | Prevention and treatment of atrial fibrillation | |
| JP2021535168A5 (https=) | ||
| JP2023536067A5 (https=) | ||
| WO2023069923A1 (en) | Compositions and methods relating to epigenetic modulation | |
| EP4301863A1 (en) | Compositions and methods for the treatment of hemophilia |